Antibodies to CD23, derivatives thereof, and their therapeutic uses
AssigneeGlaxo Wellcome Inc.
InventorsJean-Yves Marcel Paul Bonnefoy, James Scott Crowe, Jonathan Henry Ellis, Nicholas Timothy Rapson, Jean Shearin
Life of this patent
Estimating the term…
Abstract
The invention relates to antibodies which bind to the CD23 (FCεRII) type II molecule particularly altered antibodies including antibodies which bind to the CD23 (FCεRII) type II molecule characterized by an affinity constant equal to or greater than 1×109 Ka Mol−1, the preparation of such antibodies, pharmaceutical compositions which contain such antibodies and their use in therapy particularly in the treatment of autoimmune and inflammatory disorders.
Claims10
An isolated diagnostic monoclonal antibody binds specifically to the CD23 (FCRεII) type II molecule expressed on haematopoietic cells, said monoclonal antibody comprising light chain variable domains CDRL1, CDRL2, and CDRL3, further comprising heavy chain variable domains CDRH1, CDRH2, and CDRH3, wherein CDRL1 consists of the amino acid sequence RSSKSLLY KDGKTYLN of SEQ ID NO:1, CDRL2 consists of the amino acid sequence LMSTRAS of SEQ ID NO:5, CDRL3 consists of the amino acid sequence QQLVEYPFT of SEQ ID NO:7, CDRH1 consists of the amino acid sequence GYWMS of SEQ ID NO:9, CDRH2 consists of amino acid sequence EIRLKSDNYATHYAESVKG of SEQ ID NO:11, and CDHR3 consists of amino acid sequence FID of SEQ ID NO:13.
An isolated diagnostic antibody that binds to the CD23 (FCRεII) type II molecule expressed on haematopoietic cells comprising both of the amino acid sequences encoded by the nucleotide sequences according to SEQ ID NO:1 and SEQ ID NO:2.
An isolated diagnostic antibody that binds to the CD23 (FCRεII) type II molecule expressed on haematopoietic cells comprising both of the amino acid sequences encoded by the nucleotide sequences according to SEQ ID NO:17 and SEQ ID NO:18.
Dependencies are inferred from the claim text.